Charles Carey, MD
Cardiovascular Disease · Saint Louis, MONPI 1104822014
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 63.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $5,933 and has fallen 82.3% since, to $1,050 in 2025.
Across 204 payments — averaging $49.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Abbott$2K
- Boston Scientific$261
- Pfizer$181
- Abiomed$143
- E.r. Squibb & Sons, L.L.C.$135
- plus $551 from 13 others
Across 13 payments — averaging $10,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$119K
- AstraZeneca$16K
What the payments were for
- Speaking & faculty fees$5,41154%
- Food & beverage$4,12841%
- Education$5255%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 116 | $6,412 |
| Abbott | 43 | $2,382 |
| Boston Scientific | 4 | $261 |
| Pfizer | 10 | $181 |
| Abiomed | 3 | $143 |
| E.r. Squibb & Sons, L.L.C. | 2 | $135 |
| Amgen | 5 | $71 |
| Johnson & Johnson | 2 | $70 |
| AstraZeneca | 4 | $65 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $64 |
| Cvrx, Inc. | 2 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Merck | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $19 |
| Bayer | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$5,411
- CARDIOMEMS$681
- CardioMEMS HF System$525
- WATCHMAN FLX$105
How this compares
$10,064 in reported general payments places this provider in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 944 | $1,099,350 |
| EntrestoSacubitril/Valsartan | 360 | $398,817 |
| FarxigaDapagliflozin Propanediol | 336 | $326,832 |
| JardianceEmpagliflozin | 255 | $303,162 |
| XareltoRivaroxaban | 258 | $244,361 |
| MultaqDronedarone Hcl | 143 | $221,335 |
| CamzyosMavacamten | 12 | $99,535 |
| Repatha SureclickEvolocumab | 104 | $91,430 |
| NexletolBempedoic Acid | 20 | $21,655 |
| Ezetimibe | 990 | $21,550 |
| Praluent PenAlirocumab | 32 | $19,427 |
| Torsemide | 849 | $16,028 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 43 | $13,114 |
| Metoprolol Succinate | 1,003 | $12,744 |
| Rosuvastatin Calcium | 940 | $11,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $181 | $1,099,350944 claims |
| NovartisEntresto | $6,412 | $398,817360 claims |
| AstraZenecaFarxiga, Brilinta | $65 | $337,599351 claims |
| Boehringer IngelheimJardiance, Pradaxa | $19 | $309,090270 claims |
| Johnson & JohnsonXarelto | $70 | $244,361258 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $135 | $99,53512 claims |
| Esperion Therapeutics, Inc.Nexletol | $14 | $21,65520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.